New selective and potent class I HDAC inhibitor from Merck activates HIV latency ex vivo Aug. 28, 2019 No Comments
CytoDyn provides update on its HIV dose-escalating monotherapy trial of leronlimab Aug. 16, 2019 No Comments
RSS